Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 74-82

  Kovacs, Zsofia ^a   Werner, Beat ^a   Rassi, Anahita ^a   Sass, Jörn Oliver ^a   Martin Fiori, Ernst ^a   Bernasconi, Michele ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Blood brain barrier; Focused ultrasound; Glioblastoma; Micro bubbles; Syngenic mouse cancer models

Indexed keywords

BRAIN; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASE CONTROL; TUMORS; ULTRASONICS;

BLOOD-BRAIN BARRIER; CANCER MODELS; FOCUSED ULTRASOUND; GLIOBLASTOMAS; MICRO-BUBBLE;

BLOOD;

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; ECHOGRAPHY; FEMALE; GLIOBLASTOMA; GLIOMA CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICROBUBBLE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; SPECTROFLUOROMETRY; ANIMAL; BRAIN; BRAIN NEOPLASMS; METABOLISM; TUMOR CELL LINE; ULTRASOUND;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; MICE; MICROBUBBLES; SONICATION;

EID: 84902104828     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.033     Document Type: Article

References (64)

1. J.T. Huse, E. Holland, and L.M. DeAngelis Glioblastoma: molecular analysis and clinical implications Annu. Rev. Med. 64 2013 59 70
2. P.Y. Wen, and S. Kesari Malignant gliomas in adults N. Engl. J. Med. 359 2008 492 507
3. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, R.O. Mirimanoff on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
4. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, L. Mariani, J.E. Bromberg, P. Hau, R.O. Mirimanoff, J.G. Cairncross, R.C. Janzer, and R. Stupp MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
5. W.M. Pardridge Blood-brain barrier delivery Drug Discov. Today 12 2007 54 61
6. N.E. Breslow, S.S. Ou, J.B. Beckwith, G.M. Haase, J.A. Kalapurakal, M.L. Ritchey, R.C. Shamberger, P.R. Thomas, G.J. D'Angio, and D.M. Green Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies Cancer 101 2004 1072 1080
7. R. Nair, G. Ramakrishnan, N.N. Nair, T.K. Saikia, P.M. Parikh, S.R. Joshi, C.S. Soman, M. Mukhadan, K.T. Dinshaw, and S.H. Advani A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma Cancer 82 1998 2282 2288
8. R. Petrioli, A.I. Fiaschi, E. Francini, A. Pascucci, and G. Francini The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer Cancer Treat. Rev. 34 2008 710 718
9. R. Danesi, S. Fogli, A. Gennari, P. Conte, and M. Del Tacca Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs Clin. Pharmacokinet. 41 2002 431 444
10. M.F. Fung, G.V. Krepart, R.J. Lotocki, and M. Heywood Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate Obstet. Gynecol. 78 1991 1033 1038
11. S.M. Blaney, M.A. Smith, and J.L. Grem Doxorubicin: role in the treatment of osteosarcoma Cancer Treat. Res. 62 1993 55 73
12. J. Aisner, M. Whitacre, J. Abrams, and K. Propert Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung Semin. Oncol. 13 1986 54 62
13. P. Dombernowsky, J. Gehl, M. Boesgaard, T.P. Jensen, B.W. Jensen, and B. Ejlertsen Treatment of metastatic breast cancer with paclitaxel and doxorubicin Semin. Oncol. 22 1995 13 17
14. C. Carvalho, R.X. Santos, S. Cardoso, S. Correia, P.J. Oliveira, M.S. Santos, and P.I. Moreira Doxorubicin: the good, the bad and the ugly effect Curr. Med. Chem. 16 2009 3267 3285
15. G.D. Kruh, and L.J. Goldstein Doxorubicin and multidrug resistance Curr. Opin. Oncol. 5 1993 1029 1034
16. H.J. Broxterman, K.J. Gotink, and H.M. Verheul Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib Drug Resist. Updat. 12 2009 114 126
17. T. Safra, F. Muggia, S. Jeffers, D.D. Tsao-Wei, S. Groshen, O. Lyass, R. Henderson, G. Berry, and A. Gabizon Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 Ann. Oncol. 11 2000 1029 1033
18. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436
19. T. Tejada-Berges, C.O. Granai, M. Gordinier, and W. Gajewski Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer Expert. Rev. Anticancer. Ther. 2 2002 143 150
20. S. Wagner, O. Peters, C. Fels, G. Janssen, A.K. Liebeskind, A. Sauerbrey, M. Suttorp, P. Hau, and J.E. Wolff Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors J. Neurooncol. 86 2008 175 181
21. S.L. Chua, M.A. Rosenthal, S.S. Wong, D.M. Ashley, A.M. Woods, A. Dowling, and L.M. Cher Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme Neuro. Oncol. 6 2004 38 43
22. B.F. El-Rayes, D. Ibrahim, A.F. Shields, P.M. LoRusso, M.M. Zalupski, and P.A. Philip Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors Invest. New Drugs 23 2005 57 62
23. F.M. Muggia, J.D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, M. Tan, L. Roman, B. Uziely, L. Muderspach, A. Garcia, A. Burnett, F.A. Greco, C.P. Morrow, L.J. Paradiso, and L.J. Liang Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J. Clin. Oncol. 15 1997 987 993
24. X. Pan, and R.J. Lee Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity Int. J. Pharm. 336 2007 276 283
25. C. Mamot, D.C. Drummond, C.O. Noble, V. Kallab, Z. Guo, K. Hong, D.B. Kirpotin, and J.W. Park Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res. 65 2005 11631 11638
26. J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U.B. Nielsen, J.D. Marks, D. Moore, D. Papahadjopoulos, and C.C. Benz Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8 2002 1172 1181
27. S. Xu, Y. Luo, R. Graeser, A. Warnecke, F. Kratz, P. Hauff, K. Licha, and R. Haag Development of pH-responsive core-shell nanocarriers for delivery of therapeutic and diagnostic agents Bioorg. Med. Chem. Lett. 19 2009 1030 1034
28. M. de Smet, S. Langereis, S. van den Bosch, and H. Grull Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance J. Control. Release 143 2010 120 127
29. I. Lentacker, B. Geers, J. Demeester, S.C. De Smedt, and N.N. Sanders Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved Mol. Ther. 18 2010 101 108
30. J.J. Choi, K. Selert, Z. Gao, G. Samiotaki, B. Baseri, and E.E. Konofagou Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies J. Cereb. Blood Flow Metab. 31 2011 725 737
31. K. Hynynen, N. McDannold, N.A. Sheikov, F.A. Jolesz, and N. Vykhodtseva Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications Neuroimage 24 2005 12 20
32. K. Hynynen, N. McDannold, N. Vykhodtseva, S. Raymond, R. Weissleder, F.A. Jolesz, and N. Sheikov Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery J. Neurosurg. 105 2006 445 454
33. F.Y. Yang, M.C. Teng, M. Lu, H.F. Liang, Y.R. Lee, C.C. Yen, M.L. Liang, and T.T. Wong Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound Int. J. Nanomedicine 7 2012 965 974
34. M. Aryal, N. Vykhodtseva, Y.Z. Zhang, J. Park, and N. McDannold Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model J. Control. Release 169 2013 103 111
35. L.H. Treat, N. McDannold, Y. Zhang, N. Vykhodtseva, and K. Hynynen Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma Ultrasound Med. Biol. 38 2012 1716 1725
36. N. Yokomichi, T. Nagasawa, A. Coler-Reilly, H. Suzuki, Y. Kubota, R. Yoshioka, A. Tozawa, N. Suzuki, and Y. Yamaguchi Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin Hum. Cell 26 2013 8 18
37. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, E. Libson, F.M. Muggia, and A. Gabizon Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
38. O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N.I. Heshing, M. Lotem, G. Brufman, and A. Gabizon Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 2000 1037 1047
39. A.M. Seligman, and M.J. Shear Experimental production of brain tumors in mice with methylcholanthrene Am. J. Cancer 37 1939 364 395
40. R.D. Serano, C.N. Pegram, and D.D. Bigner Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA) Acta Neuropathol. 51 1980 53 64
41. M. Schneider, B. Anantharam, M. Arditi, D. Bokor, A. Broillet, P. Bussat, X. Fouillet, P. Frinking, I. Tardy, J. Terrettaz, R. Senior, and F. Tranquart BR38, a new ultrasound blood pool agent Invest. Radiol. 46 2011 486 494
42. N. Blau, L. Bonafé, and M. Blaskovics Disorders of phenylalanine and tetrahydrobiopterin metabolism N. Blau, M. Duran, M. Blaskovics, K.M. Gibson, Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases 2003 Springer Berlin Heidelberg 89 106
43. C.S. Hughes, S.L. Vaden, C.A. Manaugh, G.S. Price, and L.C. Hudson Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats J. Neurooncol. 37 1998 45 54
44. A. Rahman, D. Carmichael, M. Harris, and J.K. Roh Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes Cancer Res. 46 1986 2295 2299
45. E.W. Newcomb, and D. Zagzag The murine GL261 glioma experimental model to assess novel brain tumor treatments E.G. Van Meir, CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 2009 CNS Cancer, Cancer Drug Discovery and Development 227 241
46. D. Zagzag, D.C. Miller, L. Chiriboga, H. Yee, and E.W. Newcomb Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo Brain Pathol. 13 2003 34 37
47. C.K. Anders, B. Adamo, O. Karginova, A.M. Deal, S. Rawal, D. Darr, A. Schorzman, C. Santos, R. Bash, T. Kafri, L. Carey, C.R. Miller, C.M. Perou, N. Sharpless, and W.C. Zamboni Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer PLoS One 8 2013 e61359
48. L.H. Treat, N. McDannold, N. Vykhodtseva, Y. Zhang, K. Tam, and K. Hynynen Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound Int. J. Cancer 121 2007 901 907
49. K.M. Laginha, S. Verwoert, G.J. Charrois, and T.M. Allen Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors Clin. Cancer Res. 11 2005 6944 6949
50. J. Cummings, and C.S. McArdle Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug Br. J. Cancer 53 1986 835 838
51. S. Stallard, J.G. Morrison, W.D. George, and S.B. Kaye Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother. Pharmacol. 25 1990 286 290
52. Y.T. Lee, K.K. Chan, P.A. Harris, and J.L. Cohen Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration Cancer 45 1980 2231 2239
53. H. Yan, C. Cheng, A. Haouala, T. Krueger, J.P. Ballini, S. Peters, L.A. Decosterd, I. Letovanec, H.B. Ris, and S. Andrejevic-Blant Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model Ann. Thorac. Surg. 85 2008 1225 1232
54. F.Y. Yang, H.E. Wang, R.S. Liu, M.C. Teng, J.J. Li, M. Lu, M.C. Wei, and T.T. Wong Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound PLoS One 7 2012 e45468
55. F.Y. Yang, T.T. Wong, M.C. Teng, R.S. Liu, M. Lu, H.F. Liang, and M.C. Wei Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme J. Control. Release 160 2012 652 658
56. J. Park, Y. Zhang, N. Vykhodtseva, F.A. Jolesz, and N.J. McDannold The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound J. Control. Release 162 2012 134 142
57. K.C. Wei, P.C. Chu, H.Y. Wang, C.Y. Huang, P.Y. Chen, H.C. Tsai, Y.J. Lu, P.Y. Lee, I.C. Tseng, L.Y. Feng, P.W. Hsu, T.C. Yen, and H.L. Liu Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study PLoS One 8 2013 e58995
58. E.A. Maher, F.B. Furnari, R.M. Bachoo, D.H. Rowitch, D.N. Louis, W.K. Cavenee, and R.A. DePinho Malignant glioma: genetics and biology of a grave matter Genes Dev. 15 2001 1311 1333
59. J.H. Lagerlof, J. Kindblom, and P. Bernhardt 3D modeling of effects of increased oxygenation and activity concentration in tumors treated with radionuclides and antiangiogenic drugs Med. Phys. 38 2011 4888 4893
60. B. Kusters, W.P. Leenders, P. Wesseling, D. Smits, K. Verrijp, D.J. Ruiter, J.P. Peters, A.J. van Der Kogel, and R.M. de Waal Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis Cancer Res. 62 2002 341 345
61. W. Leenders, B. Kusters, J. Pikkemaat, P. Wesseling, D. Ruiter, A. Heerschap, J. Barentsz, and R.M. de Waal Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI Int. J. Cancer 105 2003 437 443
62. R.K. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers J. Clin. Oncol. 31 2013 2205 2218
63. D. Jeanmonod, B. Werner, A. Morel, L. Michels, E. Zadicario, G. Schiff, and E. Martin Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain Neurosurg. Focus. 32 2012 E1
64. N. McDannold, C.D. Arvanitis, N. Vykhodtseva, and M.S. Livingstone Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques Cancer Res. 72 2012 3652 3663